Government Says No Authorization Has Been Granted as Ethical Concerns Grow Over Proposed Study Involving Thousands of Babies
Developed, Researched & Published by PK-News.com
PK-News Digital News & Research Desk
BISSAU, GUINEA-BISSAU — October 14, 2026: Guinea-Bissau’s transitional government has denied approving a controversial clinical trial involving the hepatitis B vaccine in newborn babies, raising fresh questions about the future of a proposed research project that has attracted international attention and serious ethical concerns.
The government’s announcement followed reports suggesting that the United States-funded study had received permission to proceed in the West African country. Health Minister Quinhin Nantote clarified that the government had not authorized the trial, emphasizing that research involving human participants, particularly newborn children, must comply with national laws, scientific review procedures and internationally recognized ethical standards.
The clarification has renewed debate over the responsibilities of governments, researchers and international funding institutions when conducting medical studies involving vulnerable populations.
Government Demands Proper Review
Guinea-Bissau’s health authorities have stressed that no clinical research involving children should proceed without the appropriate regulatory authorization and ethical safeguards. The health minister’s statement also highlights the importance of national oversight when foreign institutions propose medical research within another country.
The disagreement over the study’s approval status emerged after earlier reports indicated that the project could move forward. Questions had already been raised about whether the research protocol had undergone all the necessary reviews and whether its design adequately protected participating infants.
The government has not provided a detailed timetable for the next steps in the review process. The study’s future therefore remains uncertain.
What the Proposed Vaccine Trial Involves
The proposed study is designed to examine the broader health effects of administering the hepatitis B vaccine at birth. Researchers have planned to involve approximately 14,000 newborns, with one group receiving the vaccine shortly after birth and another receiving it later, at around six weeks of age.
The project has attracted attention because the two groups would follow different vaccination schedules. Critics argue that delaying the birth dose for some babies could expose them to a preventable infection, particularly in a country where hepatitis B remains a significant public health concern.
The research has been associated with Danish researchers and has received funding from the United States government. However, the funding and scientific objectives do not remove the requirement for authorization from the country where the study would take place.
The central question remains whether the proposed design can meet accepted standards for scientific necessity, informed consent and the protection of newborn participants.




International Health Experts Raise Ethical Concerns
The World Health Organization has previously expressed significant concerns about the proposed trial, particularly the possibility that some newborns could be denied timely access to a vaccine with an established record of safety and effectiveness.
According to the WHO, administering the hepatitis B vaccine within 24 hours of birth is an important measure for preventing mother-to-child transmission. Infection acquired during childbirth can develop into a chronic condition, increasing the risk of serious liver disease, including cirrhosis and liver cancer later in life.
The organization has argued that research involving a control group that does not receive an established intervention requires a strong scientific justification and appropriate ethical protections. These concerns have made the Guinea-Bissau proposal a subject of wider international debate.
Why Hepatitis B Prevention Matters
Hepatitis B is a viral infection that affects the liver and can cause both short-term and lifelong illness. Transmission can occur from an infected mother to her baby during childbirth, making early prevention particularly important.
Guinea-Bissau faces considerable challenges in expanding healthcare services and improving vaccination coverage. Public health experts have emphasized that strengthening access to established preventive measures could help protect newborns and reduce the long-term burden of liver disease.
The debate over the trial also raises broader questions about medical research in lower-income countries, including whether participating communities receive adequate protection and whether research priorities reflect their healthcare needs.
What Happens Next?
The immediate priority is to establish the trial’s regulatory status and determine whether any revised proposal could meet the country’s scientific and ethical requirements. Further clarification from Guinea-Bissau’s authorities and the institutions involved will be important in determining the project’s future.
For now, the government’s denial makes clear that reports of approval should not be treated as confirmation of official authorization. Any decision to proceed must follow the appropriate review and approval procedures.
The controversy highlights a fundamental principle of medical research: scientific investigation must not come at the expense of participant safety. As discussions continue, protecting newborns, respecting national authority and maintaining public confidence in vaccination programmes remain central concerns.
Developed, Researched & Published by PK-News.com
PK-News Digital News & Research Desk
This report is based on publicly available information concerning the proposed study and the government’s clarification as of October 14, 2026.